您当前的位置：
首页 >
文章列表页 >
Cost-utility analysis of capivasertib combined with fulvestrant in the second-line treatment of HR+/HER2－ advanced breast cancer
更新时间：2025-12-26

    • Cost-utility analysis of capivasertib combined with fulvestrant in the second-line treatment of HR+/HER2－ advanced breast cancer

    • “According to the latest research, the second-line treatment of HR+/HER2 advanced breast cancer with capexetine combined with fluoxetine is not economical in China's health system.”
    • ZHONGGUO YAOFANG   Vol. 36, Issue 24, Pages: 3073-3078(2025)

    • DOI：10.6039/j.issn.1001-0408.2025.24.10    

      CLC： R956

    • Received：03 August 2025，

      Revised：2025-12-10，

      Accepted：10 December 2025，

      Published：30 December 2025

    移动端阅览

  • ZHANG Yang,KANG Shuo,WANG Xiaohui,et al.Cost-utility analysis of capivasertib combined with fulvestrant in the second-line treatment of HR+/HER2－ advanced breast cancer[J].ZHONGGUO YAOFANG,2025,36(24):3073-3078. DOI： 10.6039/j.issn.1001-0408.2025.24.10.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer
Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC
Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer
Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer
Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

Related Author

LIU Guoqiang
ZHANG Yuxi
GAO Shengnan
GAO Ning
FENG Bing
LIU Ran
ZHANG Ranran
LI Qian

Related Institution

Hebei Society for Integrated Drug and Health Technology Assessment
Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital
Dept. of Pharmacy， No. Hospital of the Navy of the PLA
School of International Pharmaceutical Business， China Pharmaceutical University
Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University
0